Five UK TechBio companies driving the AI revolution


The UK TechBio sector is thriving, according to a new report, with a growing number of companies pioneering ground-breaking products and services.

A BioIndustry Association (BIA) report lists the widespread adoption of artificial intelligence (AI) and machine learning (ML), the advancement of gene editing technologies, the power of engineering biology, and a growing interest from major pharmaceutical players as key trends driving the sector.

Five companies that are leading the way are highlighted in the report. These are:

  1. Exscentia

Exscientia was the first company to have an AI-designed molecule enter clinical trials and now has six drugs in clinical studies for CNS disorders, cancer and inflammatory disease.

  1. BenevolentAI

BenevolentAI’s AI-enabled drug discovery engine is designed to provide a multidimensional representation of human biology across all diseases. The company recently reported strong preclinical data for its candidate in amyotrophic lateral sclerosis.

  1. Charm Therapeutics

Charm secured new investment from Nvidia this year to develop its DragonFold platform, which can identify novel molecules through protein-ligand co-folding, and secured its first industry partner in Bristol Myers Squibb.

  1. Perspectum

A University of Oxford diagnostics spinout, Perspectum raised $55 million during its Series C investment round in 2023.

  1. BIOS Health

A pioneer in combining AI technologies and precision neurology, BIOS hopes to sequence neural biomarkers to elucidate the link to various disease states.

The BIA also spotlights early-stage companies driving innovation in this space. Among these are Brainomix, Cardia Tec, Sixfold, Turing Biosystems, Etcembly and Serna Bio.

Steve Bates, CEO of the BIA, said: “The UK has emerged as a prominent player in TechBio deal-making, trailing only the US over the last 18 months, showcasing the sector’s rapid ascent and its significance on a global scale.”

Diana Spencer, Senior Digital Content Editor, Drug Discovery World

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free